An Extension of SKY-0515 in Participants With Huntington's Disease

NCT07537075 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ENROLLING_BY_INVITATION

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington's Disease (HD)

Interventions

DRUG: SKY-0515

Sponsor

Skyhawk Therapeutics, Inc.